{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:36:49Z","timestamp":1784205409335,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"DOI":"10.1186\/s13550-026-01409-9","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T07:34:21Z","timestamp":1773041661000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictive value of interim \u00b9\u00b9C-choline PET\/CT for response to radium-223 in metastatic castration-resistant prostate cancer"],"prefix":"10.1186","volume":"16","author":[{"given":"Eman E.","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack R.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed E.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimki","family":"Haloi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A.","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindie","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Day A.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattew P.","family":"Thorpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene D.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse Tuba","family":"Kendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"1409_CR1","unstructured":"Leslie SW, Soon-Sutton TL, Skelton WP. Prostate cancer. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan\u2013. Updated 2024 Oct 4."},{"key":"1409_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2991\/jegh.k.191008.001","volume":"9","author":"C Mattiuzzi","year":"2019","unstructured":"Mattiuzzi C, Lippi G. Current cancer epidemiology. J Epidemiol Glob Health. 2019;9:217\u201322. https:\/\/doi.org\/10.2991\/jegh.k.191008.001.","journal-title":"J Epidemiol Glob Health"},{"key":"1409_CR3","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1158\/1055-9965.EPI-10-0437","volume":"19","author":"A Jemal","year":"2010","unstructured":"Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893\u2013907. https:\/\/doi.org\/10.1158\/1055-9965.EPI-10-0437.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1409_CR4","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1002\/ijc.25516","volume":"127","author":"J Ferlay","year":"2010","unstructured":"Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893\u2013917. https:\/\/doi.org\/10.1002\/ijc.25516.","journal-title":"Int J Cancer"},{"key":"1409_CR5","volume-title":"Cancer facts & Figs. 2025 [Internet]","author":"American Cancer Society","year":"2025","unstructured":"American Cancer Society. Cancer facts & Figs. 2025 [Internet]. Atlanta (GA): American Cancer Society; 2025. [cited 2025 Oct 25]."},{"key":"1409_CR6","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jama.2025.0228","volume":"333","author":"R Raychaudhuri","year":"2025","unstructured":"Raychaudhuri R, Lin DW, Montgomery RB. Prostate cancer: a review. JAMA. 2025;333:1433\u201346.","journal-title":"JAMA"},{"issue":"1","key":"1409_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/pros.24246","volume":"82","author":"M Jimbo","year":"2022","unstructured":"Jimbo M, Andrews JR, Ahmed ME, et al. <article-title update=\"added\">Prognostic role of 11C\u2010choline PET\/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy. Prostate. 2022;82(1):41\u20138. https:\/\/doi.org\/10.1002\/pros.24246.","journal-title":"Prostate"},{"key":"1409_CR8","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1002\/cncr.26392","volume":"118","author":"E Scosyrev","year":"2012","unstructured":"Scosyrev E, Messing EM, Mohile S, Golijanin D, Wu G. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer. 2012;118:3062\u201370. https:\/\/doi.org\/10.1002\/cncr.26392.","journal-title":"Cancer"},{"key":"1409_CR9","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147\u201354.","journal-title":"Lancet"},{"key":"1409_CR10","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.eururo.2020.01.012","volume":"77","author":"S Gillessen","year":"2020","unstructured":"Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced prostate cancer: report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020;77:508\u201347. https:\/\/doi.org\/10.1016\/j.eururo.2020.01.012.","journal-title":"Eur Urol"},{"key":"1409_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/bco2.116","volume":"3","author":"Y Khoshkar","year":"2022","unstructured":"Khoshkar Y, Westerberg M, Adolfsson J, et al. Mortality in men with castration-resistant prostate cancer: a long-term follow-up of a population-based real-world cohort. BJUI Compass. 2022;3:173\u201383. https:\/\/doi.org\/10.1002\/bco2.116.","journal-title":"BJUI Compass"},{"key":"1409_CR12","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1053\/hp.2000.6698","volume":"31","author":"L Bubendorf","year":"2000","unstructured":"Bubendorf L, Sch\u00f6pfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31:578\u201383. https:\/\/doi.org\/10.1053\/hp.2000.6698.","journal-title":"Hum Pathol"},{"key":"1409_CR13","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","volume":"184","author":"M N\u00f8rgaard","year":"2010","unstructured":"N\u00f8rgaard M, Jensen A, Jacobsen JB, Cetin K, Fryzek JP, S\u00f8rensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010;184:162\u20137. https:\/\/doi.org\/10.1016\/j.juro.2010.03.034.","journal-title":"J Urol"},{"key":"1409_CR14","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, et al. Updates to advanced prostate cancer: AUA\/SUO guideline (2023). J Urol. 2023;209:1082\u201390. https:\/\/doi.org\/10.1097\/JU.0000000000003452.","journal-title":"J Urol"},{"key":"1409_CR15","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1097\/JU.0000000000003452","volume":"9","author":"I Henr\u00edquez","year":"2021","unstructured":"Henr\u00edquez I, Roach M 3rd, Morgan TM, et al. Current and emerging therapies for metastatic castration-resistant prostate cancer (mCRPC). Biomedicines. 2021;9:1247. https:\/\/doi.org\/10.1097\/JU.0000000000003452.","journal-title":"Biomedicines"},{"key":"1409_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213\u201323.","journal-title":"N Engl J Med"},{"key":"1409_CR17","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.annonc.2025.05.011","volume":"36","author":"B Tombal","year":"2025","unstructured":"Tombal B, Choudhury A, Saad F, et al. Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333\/PEACE-3 trial. Ann Oncol. 2025;36:1058\u201367. https:\/\/doi.org\/10.1016\/j.annonc.2025.05.011.","journal-title":"Ann Oncol"},{"key":"1409_CR18","doi-asserted-by":"publisher","first-page":"1059122","DOI":"10.3389\/fmed.2022.1059122","volume":"9","author":"L Kostos","year":"2022","unstructured":"Kostos L, Buteau JP, Yeung T, et al. AlphaBet: combination of radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol). Front Med (Lausanne). 2022;9:1059122. https:\/\/doi.org\/10.3389\/fmed.2022.1059122.","journal-title":"Front Med (Lausanne)"},{"key":"1409_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12175604","volume":"12","author":"A Sidhu","year":"2023","unstructured":"Sidhu A, Khan N, Phillips C, et al. <article-title update=\"added\">Prevalence and prognostic implications of PSA flares during radium-223 treatment among men with metastatic castration resistant prostate cancer. J Clin Med. 2023;12:5592. https:\/\/doi.org\/10.3390\/jcm12175604.","journal-title":"J Clin Med"},{"key":"1409_CR20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/pcan.2017.6","volume":"20","author":"D Keizman","year":"2017","unstructured":"Keizman D, Fosboel MO, Reichegger H, et al. Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases\u2014analysis of an international multicenter database. Prostate Cancer Prostatic Dis. 2017;20:289\u201393.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1409_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s00259-017-3734-0","volume":"44","author":"E Etchebehere","year":"2017","unstructured":"Etchebehere E, Brito AE, Rezaee A, Langsteger W, Beheshti M. <article-title update=\"added\">Therapy assessment of bone metastatic disease in the era of 223radium. Eur J Nucl Med Mol Imaging. 2017;44:84\u201396. https:\/\/doi.org\/10.1007\/s00259-017-3734-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1409_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16152695","volume":"16","author":"M Cruz-Montijano","year":"2024","unstructured":"Cruz-Montijano M, Amo-Salas M, Cassinello-Espinosa J, Garc\u00eda-Carbonero I, Villa-Guzman JC, Garcia-Vicente AM. Predictive and prognostic [18F]fluorocholine PET\/CT radiomics nomogram in patients with castration-resistant prostate cancer with bone metastases treated with [223Ra]. Cancers. 2024;16:2695. https:\/\/doi.org\/10.3390\/cancers16152695.","journal-title":"Cancers"},{"key":"1409_CR23","doi-asserted-by":"publisher","first-page":"318","DOI":"10.7150\/thno.4008","volume":"2","author":"S Schwarzenb\u00f6ck","year":"2012","unstructured":"Schwarzenb\u00f6ck S, Souvatzoglou M, Krause BJ. Choline PET and PET\/CT in primary diagnosis and staging of prostate cancer. Theranostics. 2012;2:318\u201330.","journal-title":"Theranostics"},{"key":"1409_CR24","doi-asserted-by":"publisher","first-page":"e893","DOI":"10.1016\/j.ejrad.2012.04.027","volume":"81","author":"C Fuccio","year":"2012","unstructured":"Fuccio C, Castellucci P, Schiavina R, et al. <article-title update=\"added\">Role of 11C-choline PET\/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. Eur J Radiol. 2012;81:e893\u20136. https:\/\/doi.org\/10.1016\/j.ejrad.2012.04.027.","journal-title":"Eur J Radiol"},{"key":"1409_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ph10030068","volume":"10","author":"L Thomas","year":"2017","unstructured":"Thomas L, Balmus C, Ahmadzadehfar H, Essler M, Strunk H, Bundschuh RA. Assessment of bone metastases in patients with prostate cancer\u2014a comparison between [99mTc]bone scintigraphy and [68Ga]Ga-PSMA PET\/CT. Pharmaceuticals (Basel). 2017;10:44. https:\/\/doi.org\/10.3390\/ph10030068.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1409_CR26","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00259-014-2922-4","volume":"42","author":"C Uprimny","year":"2015","unstructured":"Uprimny C, Kroiss A, Nilica B, et al. [68Ga]PSMA ligand PET versus [18F]NaF PET: evaluation of response to [223Ra] therapy in a prostate cancer patient. Eur J Nucl Med Mol Imaging. 2015;42:362\u20133. https:\/\/doi.org\/10.1007\/s00259-014-2922-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1409_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.remnie.2022.11.005","volume":"42","author":"I Mart\u00ednez-Rodr\u00edguez","year":"2023","unstructured":"Mart\u00ednez-Rodr\u00edguez I, de Arcocha-Torres M, de la G\u00f3mez- Fuente FJ, et al. Effectiveness of [11C]choline PET\/CT in prostate cancer surveillance. Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition). 2023;42:93\u20139. https:\/\/doi.org\/10.1016\/j.remnie.2022.11.005.","journal-title":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"},{"key":"1409_CR28","first-page":"127","volume":"9","author":"G Treglia","year":"2019","unstructured":"Treglia G, Pereira Mestre R, Ferrari M, et al. Radiolabelled choline versus PSMA PET\/CT in prostate cancer restaging: a meta-analysis. Am J Nucl Med Mol Imaging. 2019;9:127\u201339.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"1409_CR29","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1053\/j.semnuclmed.2019.02.001","volume":"49","author":"E Mena","year":"2019","unstructured":"Mena E, Lindenberg LM, Choyke PL. New targets for PET molecular imaging of prostate cancer. Semin Nucl Med. 2019;49:326\u201336. https:\/\/doi.org\/10.1053\/j.semnuclmed.2019.02.001.","journal-title":"Semin Nucl Med"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-026-01409-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01409-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01409-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:20:41Z","timestamp":1776252041000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13550-026-01409-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1409"],"URL":"https:\/\/doi.org\/10.1186\/s13550-026-01409-9","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"the study was approved by the institutional review board (Approval No. 22-010856), and the requirement for informed consent was waived due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Competing interests"}}],"article-number":"64"}}